PF 6753512

Drug Profile

PF 6753512

Alternative Names: PF-06753512; PrCa VBIR

Latest Information Update: 04 Feb 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Colony stimulating factor receptor antagonists; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fms-like tyrosine kinase 3 inhibitors; Immunomodulators; Interleukin 2 stimulants; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 01 Dec 2015 Preclinical trials in Prostate cancer in USA (Parenteral) before December 2015
  • 01 Dec 2015 Phase-I clinical trials in Prostate cancer (Hormone refractory, Second-line therapy or greater, Adjuvant therapy) in USA (Parenteral)
  • 01 Dec 2015 Pfizer plans a phase I trial for Prostate cancer (Hormone refractory, Second-line therapy or greater, Adjuvant therapy) in USA (Parenteral) (NCT02616185)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top